簡要描述：Olerup廣州鴻程代理 始終致力于面向生命科學領域，從事科研機構(gòu)及生產(chǎn)企業(yè)所需的各類原料、試劑、耗材、儀器等的專業(yè)進出口公司。專門從事以抗*Beckman A63881的磁珠 現(xiàn)貨，moltox 11-101.5等現(xiàn)貨， 706020/706025現(xiàn)貨，Megazyme的大部分現(xiàn)貨
產(chǎn)品型號：廠商性質(zhì)：經(jīng)銷商更新時間：2024-06-20訪 問 量：344| 品牌 | 其他品牌 | 適用領域 | 科研 |
|---|---|---|---|
| 產(chǎn)地 | 進口 | 加工定制 | 是 |
廣州鴻程生物有限公司一家專注于生命科學的科技企業(yè)，由在國內(nèi)科研試劑領域有著豐富從業(yè)經(jīng)驗的技術(shù)團隊和管理團隊組建而成，專營進口生物試劑，科學儀器，實驗消耗品等。公司將不斷把上優(yōu)質(zhì)的產(chǎn)品引入國內(nèi)市場，滿足客戶的需求，公司也將緊跟生命科學的發(fā)展，為廣大科研工作者探索生命科學的奧秘奉獻綿薄之力.專門從事以抗*Beckman A63881的磁珠 現(xiàn)貨，moltox 11-101.5等現(xiàn)貨，transgenomic 706020/706025現(xiàn)貨，Megazyme的大部分現(xiàn)貨，LIST現(xiàn)貨，、ALZET大量現(xiàn)貨，Avanti 、tedpella 、BioLegend、Polyplus、jena bioscience、Mattek、MRC-Holland、polysciences、enzo、novus、TOCRIS、CAYMAN、Neuro Probe、cyguns、eylabs、NIBSC、chondrex、lc laboratories、BTI、etonbio
Olerup 產(chǎn)品
產(chǎn)品種類 | Olerup SSP 試劑 | ||
種類 | 產(chǎn)品名稱 | 規(guī)格（人份/盒） | 貨號 |
HLA-DR | HLA-DR low excl. Taq (12) | 12 | 101.101-12u |
HLA-DR low excl. Taq (48) | 48 | 101.101-48u | |
HLA-DR low screening excl. Taq (12) | 12 | 101.103-12u | |
HLA-DR low screening excl. Taq (48) | 48 | 101.103-48u | |
HLA-DRB1*01 excl. Taq (06) | 6 | 101.111-06u | |
HLA-DRB1*01 excl. Taq (24) | 24 | 101.111-24u | |
HLA-DRB1*03 excl. Taq (04) | 4 | 101.113-04u | |
HLA-DRB1*03 excl. Taq (24) | 24 | 101.113-24u | |
HLA-DRB1*04 excl. Taq (03) | 3 | 101.114-03u | |
HLA-DRB1*04 excl. Taq (24) | 24 | 101.114-24u | |
HLA-DRB1*07 excl. Taq (24) | 24 | 101.118-24u | |
HLA-DRB1*08 excl. Taq (04) | 4 | 101.127-04u | |
HLA-DRB1*08 excl. Taq (12) | 12 | 101.127-12u | |
HLA-DRB1*09 excl. Taq (06) | 6 | 101.120-06u | |
HLA-DRB1*10 excl. Taq (06) | 6 | 101.129-06u | |
HLA-DRB1*11 excl. Taq (03) | 3 | 101.115-03u | |
HLA-DRB1*11 excl. Taq (24) | 24 | 101.115-24u | |
HLA-DRB1*12 excl. Taq (12) | 12 | 101.128-12u | |
HLA-DRB1*13 excl. Taq (03) | 3 | 101.116-03u | |
HLA-DRB1*13 excl. Taq (24) | 24 | 101.116-24u | |
HLA-DRB1*14 excl. Taq (03) | 3 | 101.117-03u | |
HLA-DRB1*14 excl. Taq (12) | 12 | 101.117-12u | |
HLA-DRB1*1401/1454 excl. Taq (12) | 12 | 101.813-12u | |
HLA-DRB1*15 excl. Taq (06) | 6 | 101.125-06u | |
HLA-DRB1*15 excl. Taq (24) | 24 | 101.125-24u | |
HLA-DRB1*15/16 low excl.Taq (24) | 24 | 101.151-24u | |
HLA-DRB1*16 excl. Taq (12) | 12 | 101.126-12u | |
HLA-DRB3 excl. Taq (04) | 4 | 101.121-04u | |
HLA-DRB3 excl. Taq (24) | 24 | 101.121-24u | |
HLA-DRB4 excl. Taq (06) | 6 | 101.122-06u | |
HLA-DRB4 excl. Taq (24) | 24 | 101.122-24u | |
HLA-DRB5 excl. Taq (06) | 6 | 101.123-06u | |
HLA-DRB5 excl. Taq (24) | 24 | 101.123-24u | |
HLA-DRA excl. Taq (24) | 24 | 101.131-24u | |
HLA-DQ | HLA-DQ low excl. Taq (12) | 12 | 101.201-12u |
HLA-DQ low excl. Taq (48) | 48 | 101.201-48u | |
HLA-DQB1*02 excl. Taq (24) | 24 | 101.213-24u | |
HLA-DQB1*03 excl. Taq (06) | 6 | 101.214-06u | |
HLA-DQB1*03 excl. Taq (24) | 24 | 101.214-24u | |
HLA-DQB1*04 excl. Taq (12) | 12 | 101.215-12u | |
HLA-DQB1*05 excl. Taq (24) | 24 | 101.211-24u | |
HLA-DQB1*06 excl. Taq (04) | 4 | 101.212-04u | |
HLA-DQB1*06 excl. Taq (24) | 24 | 101.212-24u | |
HLA-DQB1*0602;DQA1*0102 excl. Taq (24) | 24 | 101.901-24u | |
HLA-DQA1 excl. Taq (04) | 4 | 101.231-04u | |
HLA-DQA1 excl. Taq (24) | 24 | 101.231-24u | |
HLA-DQA1*02, 05; DQB1*02, 0302 excl. Taq (24) | 24 | 101.903-24u | |
HLA-DP | HLA-DPA1 excl. Taq (06) | 6 | 101.331-06u |
HLA-DPA1 excl. Taq (24) | 24 | 101.331-24u | |
HLA-DPB1 excl. Taq (04) | 4 | 101.311-04u | |
HLA-DPB1 excl. Taq (24) | 24 | 101.311-24u | |
HLA-A | HLA-A low excl. Taq (12) | 12 | 101.401-12u |
HLA-A low excl. Taq (48) | 48 | 101.401-48u | |
HLA-A low screening excl. Taq (12) | 12 | 101.403-12u | |
HLA-A low screening excl. Taq (48) | 48 | 101.403-48u | |
HLA-A*01 excl. Taq (06) | 6 | 101.411-06u | |
HLA-A*01 excl. Taq (24) | 24 | 101.411-24u | |
HLA-A*02 excl. Taq (04) | 4 | 101.412-04u | |
HLA-A*02 excl. Taq (24) | 24 | 101.412-24u | |
HLA-A*03 excl. Taq (04) | 4 | 101.413-04u | |
HLA-A*03 excl. Taq (24) | 24 | 101.413-24u | |
HLA-A*11 excl. Taq (04) | 4 | 101.416-04u | |
HLA-A*11 excl. Taq (12) | 12 | 101.416-12u | |
HLA-A*23 excl. Taq (06) | 6 | 101.421-06u | |
HLA-A*24 excl. Taq (03) | 3 | 101.422-03u | |
HLA-A*24 excl. Taq (24) | 24 | 101.422-24u | |
HLA-A*25 excl. Taq (06) | 6 | 101.423-06u | |
HLA-A*26 excl. Taq (12) | 12 | 101.424-12u | |
HLA-A*29 excl. Taq (12) | 12 | 101.428-12u | |
HLA-A*30 excl. Taq (12) | 12 | 101.429-12u | |
HLA-A*31 excl. Taq (12) | 12 | 101.430-12u | |
HLA-A*32 excl. Taq (12) | 12 | 101.431-12u | |
HLA-A*33 excl. Taq (12) | 12 | 101.432-12u | |
HLA-A*34 excl. Taq (06) | 6 | 101.425-06u | |
HLA-A*36 excl. Taq (06) | 6 | 101.419-06u | |
HLA-A*66 excl. Taq (06) | 6 | 101.427-06u | |
HLA-A*68 excl. Taq (04) | 4 | 101.418-04u | |
HLA-A*68 excl. Taq (12) | 12 | 101.418-12u | |
HLA-A*74 excl. Taq (06) | 6 | 101.433-06u | |
HLA-A*80 excl. Taq (06) | 6 | 101.434-06u | |
上一篇：NVIGEN廣州鴻程代理
